Antigenics (NASDAQ: AGEN) On Tuesday announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 (HSV-2), the virus that causes genital herpes, in infected patients. "I believe these data represent the first finding of their kind in genital herpes treatments--showing a vaccine, AG-707, elicits both CD4+ and CD8+ T-cell responses in humans," said David Koelle, M.D., study investigator and professor of Medicine, Laboratory Medicine and Global Health Medicine, University of Washington. Data will be presented at the International Herpes Workshop annual meeting in Salt Lake City, Utah, on July 27 by study investigator, Dr. Koelle. Shares of the company shot up more than 13% in pre-market trading.
NetSol Technologies, Inc. (NASDAQ: NTWK) announced Tuesday that the company's board of directors has authorized a share repurchase program for up to 2 million shares of the Company's common stock. The plan went into effect July 27 and is scheduled to be completed within six months.
Disclosure: Author doesn't own any of the stocks discussed here.